These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 20021428)

  • 1. Emerging therapeutic strategies for hepatitis C virus infection.
    Sato K; Takagi H; Ichikawa T; Kakizaki S; Mori M
    Curr Mol Pharmacol; 2008 Jun; 1(2):130-50. PubMed ID: 20021428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virus.
    Takebe Y; Saucedo CJ; Lund G; Uenishi R; Hase S; Tsuchiura T; Kneteman N; Ramessar K; Tyrrell DL; Shirakura M; Wakita T; McMahon JB; O'Keefe BR
    PLoS One; 2013; 8(5):e64449. PubMed ID: 23700478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C virus replication in mouse cells is restricted by IFN-dependent and -independent mechanisms.
    Nandakumar R; Finsterbusch K; Lipps C; Neumann B; Grashoff M; Nair S; Hochnadel I; Lienenklaus S; Wappler I; Steinmann E; Hauser H; Pietschmann T; Kröger A
    Gastroenterology; 2013 Dec; 145(6):1414-23.e1. PubMed ID: 23973921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
    Suzuki T
    Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Procyanidin B1 purified from Cinnamomi cortex suppresses hepatitis C virus replication.
    Li S; Kodama EN; Inoue Y; Tani H; Matsuura Y; Zhang J; Tanaka T; Hattori T
    Antivir Chem Chemother; 2010 Aug; 20(6):239-48. PubMed ID: 20710064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
    Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
    Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New perspectives in HCV therapy: entry inhibitors.
    Donia M; Cacopardo B; Libra M; Scalia G; McCubrey JA; Nicoletti F
    Recent Pat Antiinfect Drug Discov; 2010 Nov; 5(3):181-94. PubMed ID: 20497122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Existing and future therapeutic options for hepatitis C virus infection.
    Bretner M
    Acta Biochim Pol; 2005; 52(1):57-70. PubMed ID: 15827606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of host metabolism as a target of new antivirals.
    Ikeda M; Kato N
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1277-89. PubMed ID: 17897752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of Pycnogenol® on hepatitis C virus replication.
    Ezzikouri S; Nishimura T; Kohara M; Benjelloun S; Kino Y; Inoue K; Matsumori A; Tsukiyama-Kohara K
    Antiviral Res; 2015 Jan; 113():93-102. PubMed ID: 25446333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCV research and anti-HCV drug discovery: toward the next generation.
    Wakita T
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1196-9. PubMed ID: 17905463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Entry inhibitors: New advances in HCV treatment.
    Qian XJ; Zhu YZ; Zhao P; Qi ZT
    Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging host cell targets for hepatitis C therapy.
    He Y; Duan W; Tan SL
    Drug Discov Today; 2007 Mar; 12(5-6):209-17. PubMed ID: 17331885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bridging basic science and clinical research: the EASL Monothematic Conference on Translational Research in Viral Hepatitis.
    Boettler T; Moradpour D; Thimme R; Zoulim F
    J Hepatol; 2014 Sep; 61(3):696-705. PubMed ID: 24845610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver-specific mono-unsaturated fatty acid synthase-1 inhibitor for anti-hepatitis C treatment.
    Nio Y; Hasegawa H; Okamura H; Miyayama Y; Akahori Y; Hijikata M
    Antiviral Res; 2016 Aug; 132():262-7. PubMed ID: 27392483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Pawlotsky JM; Chevaliez S; McHutchison JG
    Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experimental models for hepatitis C virus (HCV): new opportunities for combating hepatitis C.
    Trujillo-Murillo Kdel C; Garza-Rodríguez Mdel L; Martínez-Rodríguez HG; Barrera-Saldaña HA; Bosques-Padilla F; Ramos-Jiménez J; Rivas-Estilla AM
    Ann Hepatol; 2004; 3(2):54-62. PubMed ID: 15257247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity-based and fraction-guided analysis of Phyllanthus urinaria identifies loliolide as a potent inhibitor of hepatitis C virus entry.
    Chung CY; Liu CH; Burnouf T; Wang GH; Chang SP; Jassey A; Tai CJ; Tai CJ; Huang CJ; Richardson CD; Yen MH; Lin CC; Lin LT
    Antiviral Res; 2016 Jun; 130():58-68. PubMed ID: 27012176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.